Lucas, K., Lopez, P., Lawitz, E., Sheikh, A., Aizenberg, D., Hsia, S., Bee, G. B., Vierling, J., Frias, J., White, J., Eguchi, Y., Lazas, D., Neff, G., Yoneda, M., Augustin, S., Kim, W., Loeffler, Y., Schaefer, F., Lamle, S., Martic, M., Brass, C., & Sanyal, A. (n.d.). tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results. Digestive and liver disease, 52, e38–. http://access.bl.uk/ark:/81055/vdc_100101587896.0x000022